mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Takeda applies for additional indications for lansoprazole

Posted on 25/11/2009 in Pharmaceutical Company Product News

Takeda revealed this week that it has submitted an application for further indications regarding its Takepron Capsules 15 and Takepron OD Tablet 15 (lansoprazole).

Lansoprazole is a proton pump inhibitor which has already been approved for the treatment of gastric ulcers, duodenal ulcers and reflux esophagitis in patients treated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Now the firm is hoping to receive confirmation that the therapy can be used in those undergoing long-term treatment with NSAIDs to prevent the onset of gastric ulcers.

NSAIDS, while intended to curb pain, fever and inflammation, can also bring about the onset of gastric ulcers in patients that are prescribed them.

Takeda is aiming to tackle this issue by introducing lansoprazole as an option to those being treated with NSAIDs for rheumatoid arthritis and osteoarthritis.

In other company news this month, the firm establish the Takeda Wellbeing Programme 2009 - which is entitled Giving Children in Long-term Treatment the Energy to Live.

Other news stories from 25/11/2009

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Takeda makes milestone payment to Affymax over Hematide development

Takeda to conduct phase III trial of new obesity drug

Takeda launches new phase III trial of Hematide

Takeda reports latest financial results

Takeda announces EU availability of Mepact

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use